This document summarizes 4 case studies of cancer patients who were treated with Ayurveda. The first case was a patient with renal cell carcinoma that had metastasized to bones. After 3 months of Ayurvedic treatment, the bone lesions regressed and after 8 months the disease had completely resolved, with no recurrence over 8.5 years. The second case was a patient with unknown primary cancer that had metastasized extensively to bones and lungs. After 4.5 years of Ayurvedic treatment, the progression of disease was curtailed with no serious adverse events. The third case was a patient with metastatic malignant melanoma whose skin lesions reduced by 50% after 2.5 months of Ayurvedic treatment without
2. Om Saha Nau-Avatu | Om, May we all be protected
Saha Nau Bhunaktu |
Saha Viiryam
Karavaavahai |
Tejasvi Nau-
Adhiitam-Astu
Maa Vidvishaavahai |
Om Shaantih Shaantih
Shaantih ||
May we all be nourished
May we work together with
great energy
May our intellect be
sharpened
Let there be no Animosity
amongst us
Om, peace (in me), peace
(in nature), peace (in divine
forces)
Kathopanishad
4. Role of Ayurveda in Managing
Cancer
Case Studies
Understanding Cancer
Ayurveda Concepts
Ayurvedic Management
Q & A
5. Role of Ayurveda in Managing
Cancer
Case Studies
Bone metastases in renal cell carcinoma
Extensive bone and lung metastases in cancer of
unknown primary (CUP)
Malignant Melanoma
Severe ano-rectal Pain in a Case of Metastatic Breast
Cancer
6. RCC with Bone Metastases
Renal cell carcinoma (RCC) is the most common
malignancy of the kidney [Jemal et al. 2009]
Almost 30% of patients with RCC present with metastatic
disease
Bone is the common site of distant metastatic spread in
patients with advanced RCC [Motzer et al. 2007, 2008].
Metastatic bone disease causes significant morbidity
through skeletal related events (SREs)
7. RCC with Bone metastases
The prognosis for any treated renal cell cancer patient
with progressing, recurring, or relapsing disease is
poor, regardless of cell type or stage.
Almost all patients with stage IV renal cell cancer are
incurable (Kidney. In: Edge SB, Byrd DR, Compton CC, et al., eds.:
AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010)
8. RCC with Bone metastases
The incidence of spontaneous regression of metastatic
renal cell carcinoma is thought to be less than 1% of all
cases. It is reported that complete regression is even
rarer than partial regression
Since 2005, when targeted agents with activity against
RCC began to appear, the median survival for patients
with metastatic RCC has increased from 10 months to
more than 20 months
9. RCC with Bone Metastases
We present a case of RCC with bone metastases, whose
bone lesions were completely resolved after the
ayurvedic treatment.
10. RCC with Bone Metastases
26/11/2004 Male, age 41 yrs
C/o severe pain in the upper back, pain in the right
flank and right side of the chest - over mid axillary
line - since 15-20 days, which increased on cough
impulse. He also complained of cough, pain and
throat irritation
Painful body movements and pain in the left knee
joint
11. RCC with Bone metastases
H/o Presenting Complaints
k/c/o right renal cell carcinoma (RCC) Grade II, with
multiple bone metastases (Stage IV)
Had pain in the ribcage bilaterally, since December 2001.
His physician advised him some NSAIDs. However, even
after 2 months of treatment, the pain persisted. He was
then advised bone scan.
12. RCC with Bone metastases
21/2/2002 Bone scan :
revealed focal lesions on the
costochondral junction of
1st rib (both sides), 4th, 5th
ribs (right side), 3rd rib (left
side) and on D10, L1, L2, L3
vertebrae.
13. RCC with Bone metastases
23/2/2002 MRI of L.S.
Spine: revealed definite
lesions on spine, involving
the D10 pedicals and D9
body. A mass was also seen
in the right kidney (3.5 cm
x 3 cm), strongly s/o a
renal cell Ca.
14. RCC with Bone metastases
6/3/2002 : FNAC
from the lesion
confirmed RCC.
15. RCC with Bone metastases
On 11/3/2002, right radical nephrectomy was done.
The histopathology report confirmed Renal Cell Ca Grade
II, Stage IV
16. RCC with Bone metastases
March 2002: Conventional Treatment
• Inj. Disodium Pamidronate
• Inj. Intreferon alpha
• Inj Interlukin II
17. Follow Up After Conventional
Treatment
1.11.02 : Bone scan: (@ 8 months)
Show abnormal tracer uptake– lateral end of left clavicle,
right 10th rib postero laterally, L2 vertebra, tarsal region
of the right foot and right calcaneum. The rest of the
skeletal system shows normal tracer uptake. Left kidney is
normal. Above mentioned osseous abnormalities appear
like metastatic lesions
18. Follow Up After Conventional
Treatment
13.11.04 : Whole body Bone Scan (31 months of
Conventional Rx)
Multiple skeletal metastases.
Fresh lesions in 7th rib left tibial tuberosity on right
side, left navicular bone and lytic lesion of the 11th rib
are seen in addition to lesion reported earlier studies.
19. RCC with Bone metastases
At this stage, the patient approached for ayurvedic
treatment.
20. Ayurvedic Treatment
26th Nov 2004
Ayurvedic poly-herbo-mineral formulations given as oral
medicines twice a day with honey
Yapan Basti; a polyherbal medicinal preparation
administered as an Enema given for 30 consecutive days
Followed by 8 Yapana Basti every 3 months.
21. Follow Up After Ayurvedic Rx
From the second week of treatment the pain and
tenderness in the rib cage gradually reduced and was
completely relived at the end of first cycle of Yapan Basti
(30 basti)
22. Follow Up After Ayurvedic Rx
22.03.05 : Whole body
Bone scan (@ 3 months):
Multiple skeletal
metastases. Lesion in left
7th rib, L2 vertebra,
medial tuberosity of right
Tibia are not visualized
suggestive of regression of
disease.
23. Follow Up After Ayurvedic Rx
26.08.05 : Bone scan (8
months after starting
ayurvedic treatment) :
No evidence of skeletal
metastases
24. Follow Up After Ayurvedic Rx
31.08.05 PET scan (@ 8
of ayurvedic treatment) :
Whole body survey is
unremarkable.
25. Follow Up After Ayurvedic Rx
18.07.06 Whole body
PET (@ 19 months)
No definitive suggestion of
any active disease on the
present whole body
21.08.06 (@ 20 months)
Ayurvedic medicines were
stopped
26. Follow Up After Ayurvedic Rx
27.07.10 Whole body PET
scan (@ 6 years) :
No suggestion of any active
disease
27. Follow Up After Ayurvedic Rx
Bone Scan 09.11.2011 (@ 6 ½
years)
No e/o osteoblastic
skeletal metastases
Sept 2014 (@ 9 years)
Asymptomatic
Clinically disease free
28. Conclusion
The disease was progressing even after 2 ½ years of
conventional treatment
The disease regressed after 3 months of ayurvedic treatment
The disease completely resolved after 8 months of ayurvedic
treatment
The patient has DFS of over 8 ½ years
The QOL is maintained
There were no adverse effects of treatment
29. Case 2
Extensive bone and lung metastases in cancer of
unknown primary (CUP)
30. Cancer of unknown primary (CUP)
CUP is diagnosed at the metastatic stage and despite
extensive diagnostic work-up the primary tumor often
remains unidentified.
80-85% of CUP have very aggressive potential and
unpredictable pattern of metastatic spread. The largest
group of these tumors is refractory to standard
chemotherapy
The overall prognosis of CUP patients is generally very
poor with a median survival of 4-12 months
[ Hainsworth JD, Gereco FA: Treatment of patients with cancer of unknown primary site. N Engl J
Med 1993, 329(4):257-263]
31. Case Report - Extensive bone and
lung metastases in CUP
Male Age 57 years, resident of Goa
He was having right pelvic pain since Jan 08
He was treated by his family physician with NSAIDs
for over 1 ½ year
As his symptoms worsened he was advised CT scan of
pelvis in June 09
32. Case Report - Extensive bone and
lung metastases in CUP
06 June 09
CT scan Pelvis : multiple
osteolytic pelvis lesions in
the right iliac bone
extending to the
acetabulam
CT scan Thorax : multiple
nodular lesions in both
lung parenchyma (s/o
metastases)
33. Case Report - Extensive bone and
lung metastases in CUP
Tumor markers : non-contributory
23 June09 patient was referred to tertiary care center in
Mumbai for further management.
34. Case Report - Extensive bone and
lung metastases in CUP
23.06.09 : CT Thorax / Abdomen and pelvis
Multiple lung parenchymal metastases are seen.
Expansile osteolytic lesions are seen in the right
iliac blade, accetabulum and sup pubic ramus.
01.07.09 : FNAC aspiration cytology of Lt lung -
Consistent with metastases of adeno-carcinoma
35. Case Report - Extensive bone and
lung metastases in CUP
08.07.09 : After extensive investigations Oncologist
remarked :
• Extensive (metastatic) disease to unknown primary
(CUP), tumor markers were non-contributory
• Plan for symptomatic care
• To consider palliative Chemo
• To try Ayurveda treatment
36. Case Report - Extensive bone and
lung metastases in CUP
10 July 09 : Patient approached for ayurvedic treatment
37. Case Report - Extensive bone and
lung metastases in CUP
10 July 09: C/o
Severe pain in right hip joint
Could walk on plain surface with support with extreme
difficulty
Severe pain in both hip joint while walking
38. Case Report - Extensive bone and
lung metastases in CUP
10.07.09 : (1 month after diagnosis):
Ayurvedic treatment
Herbo-mineral formulation, twice a day
Matra Basti fortnightly (from Oct 09)
39. Case Report - Extensive bone and
lung metastases in CUP
X-Ray Pelvis :12..11.11 CXR : 12..11.11
40. Case Report - Extensive bone and
lung metastases in CUP
29 Jan 2014
Patient was under treatment for around 4 years 9
month
He was not taking any NSAIDs or other analgesics or
any other conventional medicine
There were no SREs despite of extensive bone
metastases
Though the patient had moderate pain and restricted
movement of the hip, he was managing all his routine
work comfortably
41. Conclusion
No conventional medicines used
No SREs despite of extensive bone metastases
No drug related side-effects
The progression of disease was curtailed and the patient
survived with minimum morbidity for 5 years
43. Case – Metastatic Malignant
Melanoma
Male Age 63 yrs
Oct 2007
Boil (lesion) of skin of Rt. Heel, thigh and lower leg
Inguinal Lymphadenopathy
3 Nov 07 Histopathology
Spindle cell melanoma of the skin of the heel
44. Case - Metastatic Malignant
Melanoma
26 Nov 07 - CT Abdomen & Pelvis
Enhancing Rt. Inguinal lymphnodes likely to be
metastasis
29 Nov 2007 : Whole Body PET
e/o Rt. Inguinal LN metastasis
Dec 2007 > Immunotherapy
Lesions increased gradually
45. Case - Metastatic Malignant
Melanoma
7 August 2008 – PET
Scan
Active disease in multiple
nodules in right heel
HP: Rt. Thigh and leg
biopsy
Malignant Melanoma
Advised Hip Articulation
> Pt. refused
46. Case - Metastatic Malignant
Melanoma
8 July 09 R/o the patient came for consultation
NE c/o
Multiple nodular lesions & sever pain in the rt. Leg
Large nodular ulcerative lesion on Rt. heel
Oozing ++
Foul smell ++
Swelling ++
15 July 2009 – Ayurvedic treatment started
No Chemotherapy, No Radiation
47. 2 ½ Months After Treatment
17 Sept 09
No foul smell
No oozing
Reduction in swelling
Relief in pain
50 % reduction in Lesions
No new lesions
Patient could walk with support
48. Case - Malignant Melanoma
Before Treatment
4 July 09
2 ½ Months After Treatment
17 Sept 09
49. Conclusion
In this case of metastatic malignant melanoma the
skin lesions reduced to around 50 % in 2 ½ months of
ayurvedic treatment
No CT, RT or immunotherapy was used
50. Case 4 - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
51. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
Female Age 63 yrs Retired Professor
28/02/14 c/o
Severe perianal & rectal pain not relived with anti-inflamatory
analgesics or opioid analgesic (morphine)
since 4 months
The pain lasted for 4-5 hours
The severity of pain compelled patient to lie in bed.
She could not even stand or walk during these
episodes
52. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
H/o
DM since 5 years on OHA
HT since 15 years
Hysterectomy 2010
Fracture lt. femur 2011
53. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
H/o Presenting Illness
Nov 12 she had palpable painful lump in left breast and a
few palpable axilary lymph nodes
Few days later she developed severe ano-rectal pain
which worsened after bowel movement
The pain continued even after a course of antibiotics and
analgesics
54. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
15.12.12 MRI Pelvis
Multiple small sub cm
bilateral iliac nodes
seen.
Multiple altered signal
intensity lesions in Lt
lateral mass of S3,
bilateral iliac bones, Rt
acetabulum, Rt ischium
and neck and
intertrochentric region
of Lt femur-possibly
marrow infiltrative
lesions eg- metastasis/
myeloma.
55. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
18.12.12 Whole body PET
CT:
A moderate sized nodular
lesion in the anterior
chest wall 3.7x2.2 cm
infiltrating the skin
e/o Lt axillary and sub
pectoral adenopathy
Osseous lesion Rt.
acetabulum
56. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
15.1.13 Bone scan:
Abnormal osteoblastic
activity involving the Rt
acetabulam and Lt
anterior superior iliac
spine,
s/o skeletal mets.
Lt SI joint and Lt humeral
head are suspicious for
metastatic involvements.
57. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
10.1.13
Histopathology Lt axillary LN biopsy: Metastatic
cancer, suspicious of breast origin.
11.1.13
Histopathology IHC panel: Lt axillary LN biopsy
ER positive(60% tumour cells), PR positive (40%
tumour cells), HER2neu –negative, GCDFP 15- positive.
58. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
14.1.13 : The pain continued
Rx
Inj Zyphos 4mg/ IV once a month,
Tab Tamoxifen 20 mg od x 3 month,
Refereed to pain clinic for pain management
Tab Durogesic 25 tds
Tab PCM 625 qds
Tryptomer 10 mg HS
No CT or RT was advised
59. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
The pain continued ……
28/2/13 Approached for ayurvedic treatment
Severe anorectal pain ++
Patient was restless due to pain
O/e
P : 100, BP- 220/120, RS/CVS- N, Wt- 78,
PR- sentinel tag @ 3’O clock, pain ++
No piles/fissure/fistula noted
60. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
As the ano-rectal pain was very severe and was not
relieved with opioid analgesic decided to give
Anuvasan Basti followed by 30 Yapana basti
About an hour after giving anuvasana basti the pain was
considerably reduced and patient went home
By night the pain subsided
Yapana basti and Medicines started from 29/02/13
61. Case - Severe ano-rectal Pain in a
Case of Metastatic Breast Cancer
By 5th day the ano-rectal pain completely relieved
She removed Morphine patch on her own on 9th day
and did not take single pain killer for any pain till date
Yapana basti x 8 repeated on 6/7/13 & 28/1/14
Last F/u 20/09/14 @ 19 months
Asymptomatic
No further investigation
62. Conclusion
The presenting complaint of severe anorectal and perineal
pain, which was not relieved with morphine, etc. Had
complete relief in pain in only 5 days of treatment
No CT or RT was given
On her last visit 19/09/14 , 22 months post detection of
metastatic CA, she is asymptomatic
There is no clinical evidence of disease
63. What is Cancer?
leading cause of
death
Estimated 14.1 million
cancer cases around
the world in 2012
Expected to increase
to 24 million by 2035.
Cancer statistics, 2014
CA: A Cancer Journal for Clinicians
Volume 64, Issue 1, pages 9-29, 7 JAN 2014 DOI: 10.3322/caac.21208
http://onlinelibrary.wiley.com/doi/10.3322/caac.21208/full#caac21208-fig-0001
64. What is Cancer?
Diseases in which abnormal cells divide without
control and are able to invade other tissues.
Cancer is not just one disease but many diseases.
There are more than 100 different types of cancer.
Cancer cells can spread to other parts of the body
through the blood and lymph systems.
Most cancers are named for the organ or type of cell in
which they start – e.g. breast CA, Colon CA, Lung CA,
etc.
65. Cell Lifespan
50 and 75 trillion cells in the body
Each type of cell has its own life span
Stomach 2 days
Spermatozoa 2-3 days
Colon 3-4 days
Platelets 10 days
Skin 19-34 days
Bone 25-30 years
Brain Lifetime
66.
67. Conventional Cancer Treatment
Surgery (for local and local-regional disease)
Radiation therapy (for local and local-regional disease)
Chemotherapy (for systemic disease)
Other important methods include
Hormonal therapy
Immunotherapy
Targeted drugs
68. Defining Response to Cancer
Treatment
Cure : Long-term absence of symptoms or signs
Complete remission : Disappearance of clinical evidence
Partial response : 50% reduction in size of tumor mass or
masses
Stable disease : Neither improvement nor worsening
Disease-free survival : Interval between disappearance of
the tumor and relapse
Progression-free survival : Time from initiation of
treatment to time of overt progression in a surviving
patient
Survival time : Time from diagnosis to death
75. Ayurvedic Concepts of Disease
Manifestation and Treatment
Dosha at Cellular Level
Movement = Vata
Energy = Pitta > Agni
Bond = Kapha
Structure = Cell,
physical dhatu =tissue
Equilibrium of dosha and dhatu = Normal
cellular functions and structure
76. Ayurvedic Concepts of Disease
Manifestation and Treatment
Molecular Basis of Rx
Dosha = Function = Physiological activities
Dhatu = (Davya) = Structure = Anatomy
Disease = Vitiated Dosha + Dushya blending
77. Ayurvedic Concepts of Disease
Manifestation and Treatment
Dosha vaishamya = imbalance of the
function of the respective dosha
Dhatu vaishamya = disruption of the
cellular structure
Agni vaishamya = failure of proper
transformation
78. Physiological Changes In Dosha
Excitation
Prakopa
2
Normalcy
Prashama
3
Accumula
tion
Chaya 1
Age
Day
Night
Meal
79. Ayurvedic Concepts of Disease
Manifestation and Treatment
Excitation
Prakopa
2
Accumula
tion
Chaya 1
Normalcy
Prashama
3
Spread
Prasara 3
Occupying
Dhatu
Sign /
Symptoms
Vyakti 5
Differentiat
ion
Bheda 6
6 Stages of disease
manifestation
80. Ayurvedic Concepts of Disease
Manifestation and Treatment
D
O
S
H
A
D
U
S
H
Y
A
Causative
Factors
Vata
Pitta
Kapha
Rasa
Rakta
Mansa
Meda
Asthi
Majja
Shukra
93. Basic Treatment Modalities
Reducers
(Langhana)
Pacifiers
(Shamana)
Purifiers
(Shodhana)
Medicines that balances vitiated
dosha without removing them
from body
Panchakarma
Vamana, Virechana, Basti,
Nasya, Raktamokshana
Medicines that dislodge and
expel vitiated dosha from body
94. Pharmacokinetics
Taste (Rasa)
Change in rasa after digestion (Vipaka)
Change in Properties (Gunantara)
Potency (Veerya)
Character (Swabhava)
Incomprehensible (Vichitra pratyarabdha)
95. Rasa Properties
Augmenters
Reducers
Water
Earth
Sweet
Fire
Water
Salty
Fire
Earth
Amla
Spac
e
Air
Bitter
Fir
e
Air
Pungent
Air
Earth
Astringent
Absolute bruhana
Absolute langhana
Relative langhana
96. Reducers
Change of taste
post digestion -
Vipaka
Potency - Veerya
Sweet Acidic
Salty
Hot Cold
Independent of Digestive Fire
101. Dosha Balancing Treatment
Basti
Panchakarma of choice for vata balancing
Medicines given through rectal rout
Large intestine main place of vatadosha
Not for evacuation of bowl
Vatadosha balancing
104. Properties of Ingredients
Medicine Main Properties
Sitopaladi Churna Improves dhatu-agni,
Hirak bhasma Best rasayana, rejuvenator, fertility
promoter, aphrodisiac
Shankha bhasma Useful in reducing tumor mass
105. Properties of Ingredients
Medicine Main Properties
Abhrak bhasma Promotes strength, useful in diseases
of nervous system
Suvarna bhasma Rasayana, Increases ‘oja’,
Vayasthapana (enhances quality of
life),
Rajata Bhasma Lekhana (removes excess cells), Vata
pacifier, rejuvenator,
106. Properties of Ingredients
Medicine Main Properties
Tamra Bhasma Lekhana, useful in vata-kapha
diseases, useful in reducing tumor
mass
Bruhat Vata
Chintamani Rasa
Rasayana, strength promoter, fast
acting, vata dosha balancing
Makaradhwaja
rasa
Rasayana, improves fertility, restores
physical and psychological strength,
improves cell regeneration
107. Properties of Ingredients
Medicine Main Properties
Sheelajeet Rasayana, balances meda dhatu,
Praval Pishti Tridosha shamak, strength enhancer,
Mukta Pishti Rejuvenator, helps regeneration,
medahara, prevents bone resorption
108. Outcome
Normal Cell
Faulty Genetic
Information
(Shukra Dhatu)
Defective Control
Mechanism
(Vitiated Vata
Dosha)
Hinweis der Redaktion
Om Saha Nau-Avatu |Saha Nau Bhunaktu |Saha Viiryam Karavaavahai |Tejasvi Nau-Adhiitam-Astu Maa Vidvissaavahai |Om Shaantih Shaantih Shaantih || Kathopanisad
Renal cell carcinoma (RCC) is the most common malignancy of the kidney. In 2007, just under 58,000 people in the United States developed RCC and 12,980 died from the disease [Jemal et al. 2009]. The incidence of RCC has been increasing by about 3% per year in North Americans, with the highest rates now seen among African Americans [McLaughlin and Lipworth, 2000]. Almost 30% of patients with RCC present with metastatic disease, and furthermore, about 40% of patients who undergo resection of their primary with curative intent will relapse with disseminated disease [Motzer et al. 1996].
Bone is the second most common site of distant metastatic spread (following lung) in patients with advanced RCC. About one-third of patients in modern randomized trials of targeted therapies for advanced RCC have bone metastases [Rini et al. 2008; Motzer et al. 2007, 2008].
http://www.cancer.gov/cancertopics/pdq/treatment/renalcell/HealthProfessional/page8#Reference8.1
Kidney. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 479-89
A new era in the treatment of metastatic RCC commenced around 2005, when targeted agents with activity against RCC began to appear. Since that time, the median survival for patients with metastatic RCC has increased from 10 months to more than 20 months.
Bone metastases in patients with renal cell carcinoma (RCC) are associated with a high risk of skeletal complications. About 40% of patients with RCC develop bone metastases. RCC is the fourth most common metastatic tumor of the spine and the most common cancer to present as a neurologic deficit secondary to an undetected primary malignancy. Chemotherapy and hormone therapy are ineffective, making radiation and surgery the mainstays of treatment. Failure to respond to or relapse after radiotherapy is common (American Journal of Neuroradiology 22:997-1003 (5 2001)
The median survival time with distant metastatic RCC is around 6 months, and few cases survive beyond 2 years. The incidence of spontaneous regression of metastatic renal cell carcinoma is thought to be less than 1% of all cases. It is reported that complete regression is even rarer than partial regression
We present a case of RCC with bone metastases, whose bone lesions were completely resolved after the ayurvedic multi-modality treatment.
A new era in the treatment of metastatic RCC commenced around 2005, when targeted agents with activity against RCC began to appear. Since that time, the median survival for patients with metastatic RCC has increased from 10 months to more than 20 months.
Bone metastases in patients with renal cell carcinoma (RCC) are associated with a high risk of skeletal complications. About 40% of patients with RCC develop bone metastases. RCC is the fourth most common metastatic tumor of the spine and the most common cancer to present as a neurologic deficit secondary to an undetected primary malignancy. Chemotherapy and hormone therapy are ineffective, making radiation and surgery the mainstays of treatment. Failure to respond to or relapse after radiotherapy is common (American Journal of Neuroradiology 22:997-1003 (5 2001)
The median survival time with distant metastatic RCC is around 6 months, and few cases survive beyond 2 years. The incidence of spontaneous regression of metastatic renal cell carcinoma is thought to be less than 1% of all cases. It is reported that complete regression is even rarer than partial regression
We present a case of RCC with bone metastases, whose bone lesions were completely resolved after the ayurvedic multi-modality treatment.
Table. TNM Classification for Renal Cell Carcinoma (Open Table in a new window)
Primary tumors (T)TXPrimary tumor cannot be assessedT0No evidence of primary tumorT1Tumor ≤7 cm in greatest dimension, limited to the kidneyT1aTumor ≤4 cm in greatest dimension, limited to the kidneyT1bTumor >4 cm but ≤7 cm in greatest dimension, limited to the kidneyT2Tumor >7 cm in greatest dimension, limited to the kidneyT2aTumor >7 cm but ≤10 cm in greatest dimension, limited to the kidneyT2bTumor >10 cm, limited to the kidneyT3Tumor extends into major veins or perinephric tissues but not into the ipsilateral adrenal gland and not beyond the Gerota fasciaT3aTumor grossly extends into the renal vein or its segmental (muscle-containing) branches, or tumor invades perirenal and/or renal sinus fat but not beyond the Gerota fasciaT3bTumor grossly extends into the vena cava below the diaphragmT3cTumor grossly extends into the vena cava above the diaphragm or invades the wall of the vena cavaT4Tumor invades beyond the Gerota fascia (including contiguous extension into the ipsilateral adrenal gland)Regional lymph node (N)NXRegional lymph nodes cannot be assessedN0No regional lymph node metastasesN1metastases in regional lymph node(s)Distant metastases (M)M0No distant metastasesM1Distant metastases
Table. Anatomic stage/prognostic groups (Open Table in a new window)
StageTNMIT1N0M0IIT2N0M0IIIT1-2N1M0T3N0-1M0IVT4N2M0Any TAny NM1
In metasatic bone cancer, Pamidronate (‘Aredia’) is used, along with cancer therapy. The dual benefits of Aredia are delay and reduction of bone complications, such as fractures, and the possibility of reducing bone pain. It is the only medication approved for the treatment of bone metastases. This medication acts on bone to help regulate blood calcium levels. It is used to treat Paget's disease of bone and to treat high blood calcium levels. The medication has also been used in the treatment of osteoporosis, to reduce bone pain associated with certain illnesses and to treat bone loss due to breast cancer.
Immunotherapy was first introduced in the 1980s, and it provided another therapeutic alternative for distant metastatic RCC. The current regimens of immuno-therapy for distant metastatic RCC vary greatly but the main regimens are based on interferon alpha and interleukin-2. In comparison to cases without immuno- therapy, interferon alpha can prolong the median survival time by 2.6 months.
Interleukin-2 is one of the activators between T cells and natural killer cells. The overall survival time with interleukin-2 based adjuvant immunotherapy after a cytoreductive nephrectomy was 16.7 months in one study.
To conclude, previously, the median survival of patients with distant metastatic RCC was only 6 months. Adjuvant immunochemotherapy can increase the median survival time to more than 20 months.
Inj. Disodium Pamidronate
Inj. Intreferon alpha
Inj Interlukin II
Aredia (Inj. Disodium Pamidronate)
15mg x VIAL - Aredia INJ 2579.00 Aredia 30mg x VIAL - Aredia INJ 5158.00 Aredia 60mg x VIAL - Aredia INJ 10316.00
Intalfa 3 MIU x 1mL 1 Intalfa PFS 603.00
Interferon alfa-2a is a protein. Interferons are released in the body in response to viral infections. Interferons are important for fighting viruses in the body, regulating reproduction of cells, and regulating the immune system.Interferon alfa-2a is used to treat chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and some types of chronic myelogenous leukemia (CML).
Pharmacokinetics
Interferon alfa-2a has antiviral, antitumour and immunomodulatory activity. It inhibits replication of a wide range of RNA and DNA viruses. It also exerts antiproliferative effects on normal and malignant cells. Interferon alfa-2a suppresses antibody formation through an effect on B-lymphocytes and inhibits onset of delayed hypersensitivity.Absorption>80% is absorbed (IM); peak plasma concentrations within 4-8 hours (IM).ExcretionVia urine (negligible amounts); 3.7-8.5 hours (elimination half-life).
Interferon Alfa-2A Adverse Reactions / Interferon Alfa-2A Side Effects
Depressive illness, suicidal behaviour, irritability, insomnia, anxiety. Flu-like symptoms. Headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. GI disturbances. Dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. Inj site reaction, alopecia, rash, dry skin or pruritus. Conjunctivitis, menstrual irregularity, visual disturbances. Coughing, dyspnoea. Myalgia, joint or bone pain, arthritis or polyarthritis. Bone marrow depression.Potentially Fatal: Marked increase in triglyceride levels, GI haemorrhage, severe infections, pulmonary infiltrates or pulmonary function impairment.
No Conventional Medicines ?
Ayurvedic poly-herbo-mineral formulations given as oral medicines twice a day with honey
Therapeutic Panchakarma procedure viz Yapan Basti , a polyherbal medicinal preparation administered as an Enema given for 30 consecutive days
Mr. AK is a 50 year old male residing in Goa. He is having right pelvic pain since last 1.5 years (since Jan 08). He was treated by his family physician with NSAIDs. As his symptoms worsened even after taking medicines for long, he was advised CT scan of pelvis in June 09. In this CT scan multiple osteolytic pelvis lesions are noted in the right iliac bone extending to the acetabulam (s/o metastases). CT scan of thorax was done, which revealed multiple nodular lesions in both lung parenchyma (s/o metastases). On 23 June09 patient was referred to tertiary care center in Mumbai (Tata Hospital) for further management. After extensive investigations TATA hospital doctors 08.07.09 remarked –
Extensive (metastatic) disease to unknown primary, tumour markers were non-contributory
Plan for symptomatic care
Option of Alternative medicine (Ayurveda) given by the oncologist
Advised to consider palliative Chemo Therapy for symptom control and to maintain good general condition if symptoms are severe
On 10 July 09 patient approached for ayurvedic treatment. He was able to walk with support, walking was very painful as slight pressure on right leg worsened pain. He can manage to walk on plain surface. He cannot slip on right side as it worsens his pain.
He also complains of right hip joint pain and dribbling micturation since about last 1.5 years.
CT scan multiple osteolytic pelvis lesions are noted in the right iliac bone extending to the acetabulam (s/o metastases). CT scan of thorax was done, which revealed multiple nodular lesions in both lung parenchyma (s/o metastases)
CT Pelvis- 06.06.09
Multiple osteolytic pelvic lesions, s/o metastases. Expansile osteolytic lesions are noted in the right iliac bone extending into the acetabulum with destruction of the overlying cortex at places with extraosseus tissue component. Similar osteolytic lesions also noted in the sup pubic ramus on the right side.
CT Thorax - 06.06.09
Multiple nodular lesions are noted in both lung parenchyma s/o hematogenous metastases no lymphadenopathy.
CT Thorax / Abdomen and pelvis (P+C) at TATA Hospital: 23.06.09
Multiple lung parenchymal metastases are seen. Expansile osteolytic lesions are seen in the right iliac blade, accetabulum and sup pubic ramus.
FNAC aspiration cytology of Lt lung- 01.07.09
Consistent with metastases of adeno carcinoma
23 June09 patient was referred to tertiary care center in Mumbai (Tata Hospital) for further management. After extensive investigations TATA hospital doctors 08.07.09 remarked –
Extensive (metastatic) disease to unknown primary, tumour markers were non-contributory
Plan for symptomatic care
Option of Alternative medicine (Ayurveda) given by the oncologist
Advised to consider palliative Chemo Therapy for symptom control and to maintain good general condition if symptoms are severe
On 10 July 09 patient approached for ayurvedic treatment. He was able to walk with support, walking was very painful as slight pressure on right leg worsened pain. He can manage to walk on plain surface. He cannot slip on right side as it worsens his pain.
He also complains of right hip joint pain and dribbling micturation since about last 1.5 years.
started on
Herbo-mineral formulation, twice a day with Honey and cow’s ghee, after food,
Chandraprabha vati 2-2-2
Matra Basti fortnightly since Oct 09
Conclusion:
Disease is in status-quo condition which is important in view of extensive bone and lung metastases.
The incidence of melanoma is increasing at a dramatic rate worldwide. One in 75 Americans will have developed melanoma in the year 2000. [1] Most patients present with early-stage disease that is potentially curable with surgery alone in up to 90% of patients. However, the prognosis for patients with more advanced disease with involvement of regional lymph nodes or distant metastasis is poor, with median survival rates of 24 and 6 months, respectively. In the last few
Mrs RS is a 63 yr old, Christian lady. She got retired as a college professor…. yrs back.
As pain was severe, unbearable with all oral analgesics and Morphine patch since last 4 months, pt consulted us on 28.2.13
C/O:
Sev PR pain continuous with acute onset of nature which lasts for 5-6 hr and pt has to lie in bed as difficulty in standing / walking. In supine lying position also pt doesn’t get relief. Pt describes this pain as ‘andar se kuch khichata hai’ n so sev that she unable to move/eat during pain. There was polyurea and mild dysurea . bowl was N, sleep less/disturbed as pain use to start at any time of the day. There was mild pain in low back and hips since last 2 months. No weight loss or pain in breast or lump noted, anxiety++ and her gait was exhausted and very slow due to pain. She was unable to sit in clinic for 15-20 mins also.
Till 1st week of November 12 she was asymptomatic.
In second week of Nov 12 she developed boil over Lt breast and few axillary nodes were palpable. The lump was palpable and painful. She consulted @ Fortis Hosp, finding were inflammatory? - Infected sebaceous cyst in Lt breast. Treatment given was course of antibiotics for 5 days. After medications there was regression in axillary nodes.
By the time she developed sev pricking pain in perianal region more on Rt side which gets worse after defecation, the pain was continuous, intense and nagging in nature. She did MRI pelvis on 15.12.12 which showed multiple sub centric bilateral iliac nodes s/o metastasis.
[Q- ?? PR pain/lump was prim symptom. If pain sev then why late in consultation, what Rx did initially]
On 17.12.12 she consulted in Fortis for PR pain. There was no PR bleed, PR burning, piles or fissures. Pain severity has increased now- continuous daily pain. There was h/o constipation and straining type 1-2 on BRISTOL scale. Loss of sleep , polyurea and dysurea . There was no weight loss. PR exam/ proctoscopy were normal. She was advice T Tryptomer and further Investigation. S Creat came 1.4 with LDH 208.
Whole body PET CT Scan done on 18.12.12 showed suspicious multiple bone lesions.
As there was no relief in pain on 5th Jan 13 they consulted in SevenHills hosp.
There was PR tenderness in perianal R from 3’O clock till 6’O clock, o/e no PR spasm, ? intersphincteric abscess on the Lt side, Lt breast lump palpable LT upper and inner quadrant 3x3 cm, inflammation+ with bloody discharge. Treatment started T Ultracet, Proxyvon and Tryptomer with Softovac poder 2tsf, HS.
On 8th Jan she went in Tata. 3 mobile hard, ipsilateral lymph nodes were palpable with Lt breast lump in upper outer quadrant 2x1cm, matted. Histopath of same was advised.
She was advised biopsy of Lt breast lump by both Tata n Seven hills hosp which she did on 9th Jan.
Histopath of Lt axillary lymph node biopsy report showed metastatic cancer suspicious of breast origin. IHC panel confirmed the diagnosis as metastatic duct cancer of Lt axillary node ER/PR positive, HER2neu negative, GCDFP15 positive.
As pain was very severe which was not relived by analgesics and she diagnosed as cancer, for further opinion she again consulted in SL Raheja and Tata hosp oncology dept on 14.1.13
Dr‘s remark on her status is – pain does not correlate with the radiology findings of accetabular lesion, may be due to infective focus. Like to review Xray PBH, if no lesion appreciated RT might not be indicated.
On same date after opinion from Joint clinic, Dr Badwe advised Inj Zyphos 4mg/ IV once a month, T Tamoxifen 20 mg oncex 3 month, no RT suggested at present, pt ref to pain clinic for pain management
Pt seen in pain clinic @ Tata. Proctoscopy, PS, PV, PR, cervical examinations were normal. X ray PBH was normal. They have advised T Durogesic 25, PCM 625 qds, Tryptomer 10 mg HS, Pan40 od as creat was 1.4, in addition to Morphine patch (when gave??? ) as pain was sev & continuous.
As pain was severe, unbearable with all oral analgesics and Morphine patch since last 4 months, pt consulted us on 28.2.13
15.12.12 MRI Pelvis: (Jaipur)
No obvious collection/fistula seen in perirectal region or ischiorectal fossa. Multiple small sub cm bilateral iliac nodes seen. Multiple altered signal intensity lesions in Lt lateral mass of S3, bilateral iliac bones, Rt acetabulum, Rt ischium and neck and intertrochentric region of Lt femur-possibly marrow infiltrative lesions eg- metastasis/ myeloma.
Histopath of Lt axillary lymph node biopsy report showed metastatic cancer suspicious of breast origin. IHC panel confirmed the diagnosis as metastatic duct cancer of Lt axillary node ER/PR positive, HER2neu negative, GCDFP15 positive.
10.1.13
Histopathology Lt axillary LN biopsy: Metastatic cancer, suspicious of breast origin.
11.1.13
Histopatholgy IHC panel: Lt axillary LN biopsy
ER positive(60% tumour cells), PR positive (40% tumour cells), HER2neu –negative, GCDFP 15- positive.IHC panel confirms metastatic duct cancer of Lt axillary node.
As pain was very severe which was not relived by analgesics and she diagnosed as cancer, for further opinion she again consulted in SL Raheja and Tata hosp oncology dept on 14.1.13
Dr‘s remark on her status is – pain does not correlate with the radiology findings of accetabular lesion, may be due to infective focus. Like to review Xray PBH, if no lesion appreciated RT might not be indicated.
On same date after opinion from Joint clinic, Dr Badwe advised Inj Zyphos 4mg/ IV once a month, T Tamoxifen 20 mg oncex 3 month, no RT suggested at present, pt ref to pain clinic for pain management
Pt seen in pain clinic @ Tata. Proctoscopy, PS, PV, PR, cervical examinations were normal. X ray PBH was normal. They have advised T Durogesic 25, PCM 625 qds, Tryptomer 10 mg HS, Pan40 od as creat was 1.4, in addition to Morphine patch (when gave??? ) as pain was sev & continuous.
As pain was severe, unbearable with all oral analgesics and Morphine patch since last 4 months, pt consulted us on 28.2.13
O/E:
P 100, BP- 220/120, RS/CVS- N, Bowl- 1 or 2 , soft, Mictu- every 2-3 hrly with mild pain, wt- 78, Lt ankle swelling (H/O # Lt femur), PR- sentinel tag @ 3’O clock, pain more on 12-3 O’ clock position and somewhere mid to 3-6 O’clock position, n piles/fissure/fistula noted, not much tender to touch, no breast lump/ axillary LN palpable
As pt was in terrible pain we decided to give Matra basti stat and asked her to start yapan basti asap.
Matra basti of 40 ml of Sahachar tel with lower abdominal and perianal snehan swedan done at about 4pm. Pt retained the basti oil for 4-5 hrs and passed one soft motion around 9pm.
While going home in hour she felt pain intensity is less and become lesser till night.
As she had relief in pain and severity was reduced, from next day she opt for 30 days course of YapanB.
Next day we gave her YapanB, that day she experienced severe acute onset pain twice in a day but severity was less.
On 3rd Dy she came for basti saying there is no pain since morning, again we gaved her Yapan B.
On 4th day there was moderate pain since morn but with 60% relief in pain intensity and frequency.
On 5th Dy she told there is no pain since yest eve after B and she not took any single pain killer since morning (she took Nt’s dose as routine), her BP was settled to 140/70 with P 88 now, which we have recorded daily was 180-190 systolic and 110-100 diastolic prev (due to pain n stress)
[On 8th Dy she had C/O PR burn and sudden current like PR pain since yest eve which lasts for seconds and disappears… basti continued]
From 5th day onwards, pt didn’t complain about PR pain as she got 100% relief with basti and medicines. She removed Morphine patch on her own on 9th day and not took single pain killer for any pain till date.
O/E:
P 100, BP- 220/120, RS/CVS- N, Bowl- 1 or 2 , soft, Mictu- every 2-3 hrly with mild pain, wt- 78, Lt ankle swelling (H/O # Lt femur), PR- sentinel tag @ 3’O clock, pain more on 12-3 O’ clock position and somewhere mid to 3-6 O’clock position, n piles/fissure/fistula noted, not much tender to touch, no breast lump/ axillary LN palpable
As pt was in terrible pain we decided to give Matra basti stat and asked her to start yapan basti asap.
Matra basti of 40 ml of Sahachar tel with lower abdominal and perianal snehan swedan done at about 4pm. Pt retained the basti oil for 4-5 hrs and passed one soft motion around 9pm.
While going home in hour she felt pain intensity is less and become lesser till night.
As she had relief in pain and severity was reduced, from next day she opt for 30 days course of YapanB.
Next day we gave her YapanB, that day she experienced severe acute onset pain twice in a day but severity was less.
On 3rd Dy she came for basti saying there is no pain since morning, again we gaved her Yapan B.
On 4th day there was moderate pain since morn but with 60% relief in pain intensity and frequency.
On 5th Dy she told there is no pain since yest eve after B and she not took any single pain killer since morning (she took Nt’s dose as routine), her BP was settled to 140/70 with P 88 now, which we have recorded daily was 180-190 systolic and 110-100 diastolic prev (due to pain n stress)
[On 8th Dy she had C/O PR burn and sudden current like PR pain since yest eve which lasts for seconds and disappears… basti continued]
From 5th day onwards, pt didn’t complain about PR pain as she got 100% relief with basti and medicines. She removed Morphine patch on her own on 9th day and not took single pain killer for any pain till date.
Cancer is a leading cause of death worldwide and the total number of cases globally is increasing.
There were an estimated 14.1 million cancer cases around the world in 2012, of these 7.4 million cases were in men and 6.7 million in women. This number is expected to increase to 24 million by 2035.
Cancer is a term used for diseases in which abnormal cells divide without control and are able to invade other tissues. Cancer cells can spread to other parts of the body through the blood and lymph systems.
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer that begins in basal cells of the skin is called basal cell carcinoma.
There are between 50 and 75 trillion cells in the body.... Each type of cell has its own life span,
Cell type
Length of time
Red blood 120 days
Lymphocytes Over one year
Other white 10 hours
Platelets 10 days
Bone 25-30 years
Brain Lifetime
Colon 3-4 days
Skin 19-34 days
Spermatozoa 2-3 days
Stomach 2 days
Thus cancer often explodes in something akin to a chain reaction caused by a few errors, which compound into more severe errors. Errors which produce more errors are effectively the root cause of cancer, and also the reason that cancer is so hard to treat: even if there were 10,000,000,000 cancerous cells and one killed all but 10 of those cells, those cells (and other error-prone precancerous cells) could still self-replicate or send error-causing signals to other cells, starting the process over again. This rebellion-like scenario is an undesirable survival of the fittest, where the driving forces of evolution itself work against the body's design and enforcement of order. In fact, once cancer has begun to develop, this same force continues to drive the progression of cancer towards more invasive stages, and is called clonal evolution.[6]
When normal cells are damaged beyond repair, they are eliminated by apoptosis (A). Cancer cells avoid apoptosis and continue to multiply in an unregulated manner (B).
Curing cancer requires eliminating all cancer cells. The major modalities of therapy are
Surgery (for local and local-regional disease)
Overview of Cancer Therapy
Radiation therapy (for local and local-regional disease)
Chemotherapy (for systemic disease)
Other important methods include
Hormonal therapy (for selected cancers, eg, prostate, breast, endometrium)
Immunotherapy (monoclonal antibodies, interferons, and other biologic response modifiers and tumor vaccines—see Immunotherapy of Cancer)
Differentiating drugs such as retinoids
Targeted drugs that exploit the growing knowledge of cellular and molecular biology
Modalities of Cancer Therapy : Principles of Cancer Therapy
Surgery Primary tumor resection Resection of metastases Cytoreduction Palliative surgery Reconstructive surgery Radiation Therapy Types of radiation therapy Adverse effects Chemotherapy Cytotoxic drugs Hormonal therapy Biologic response modifiers Differentiating drugs Antiangiogenesis drugs Signal transduction inhibitors Monoclonal antibodies Vaccines Multimodality and Adjuvant Chemotherapy Adjuvant therapy Neoadjuvant therapy Bone Marrow/Stem Cell Transplantation Gene Therapy
Defining Response to Cancer Treatment Term
Cure
Long-term absence of symptoms or signs of a disease, although patients who appear to be cured may still have viable tumor cells that eventually cause relapse
Complete remission (complete response)
Disappearance of clinical evidence of disease
Partial response
> 50% reduction in size of tumor mass or masses, sometimes leading to significant palliation and prolongation of life but with inevitable regrowth of the tumor
Stable disease
Neither improvement nor worsening
Disease-free survival (disease-free interval)
Interval between disappearance of the tumor and relapse
Progression-free survival
Time from initiation of treatment to time of overt progression in a surviving patient
Survival time
Time from diagnosis to death
Pinda – Bamhanda
Human being
Universe
Dosha Dhatu Mala Mulam
The word agni is Sanskrit for "fire" (noun), cognate with Latin ignis (the root of English ignite), Russian огонь (ogon), Polish "ogień", Slovenian "ogenj", Serbo-Croatian oganj, and Lithuanian ugnis—all with the meaning "fire", with the reconstructed Proto-Indo-European root being h₁égni-. Agni has three forms: fire, lightning and the Sun.[4]
In Hindu scriptures, Agni is the God of Fire, and is present in many phases of life such as honouring of a birth (diva lamp), prayers (diva lamp), weddings (Yagna where the bride and groom circle 7 times) and death (cremation).
Vaya Aho – Ratri Bhukta
Season
Antya Madhya Adi
Vyadhi Utpatti
Kupitanam hi doshanam sharire paridhavatam ..
Vyadhi Utpatti
Vyadhi Utpatti
According to ayurved, regeneration of cells is carried out by the ‘shukra dhatu’ and is controlled by the ‘vata dosha’. The uncontrolled cell division is a result of imbalance of ‘vata dosha’, which results into neoplasm (The hypothesis of cancer).
As ‘shukra dhatu’ is ‘sarvadehik’, every cell in the body has an inbuilt potential of replication / reproduction, in favorable situations. The ‘akasha’ provides space for accommodation of such multiplying cells (as ‘garbhashaya’ – uterus provides space for growth of embryo). Any space or ‘akasha’ (Kha) is therefore a potential garbhashaya (e.g. test-tube baby). However, if such situation is created in space other than the one designated for the purpose, it is abnormal- ‘Kha-vaigunya’.
Some of the cancerous cells may be carried to such distant places with the circulation, and if they find a suitable place for harboring, they may replicate in that place if the condition is favorable (…Yatra Sanga: Khavaigunyat Vyadhi: tatropjayate). Therefore, a cancer cell can migrate to any place in the body and start multiplying and produce metastatic cancer.
Embryologically, the kidneys are created from the essence of ‘Rakta dhatu’ and ‘Meda dhatu’ (“Rakta Meda Prasadajou Vrukou”). In ayurvedic therapeutics, this reference needs to be viewed in terms of probable mode or route of samprapti (etio-pathology) and its reversal (chikitsa - treatment). Medicines which act on rasa dhatu and meda dhatu would therefore probably be helpful in treating any pathology of Kidney.
In the metastatic bone cancer, ‘Asthi’ predisposed by ‘kha vaigunya’ acts as a site which allows the growth of cells from a distant tissue. This space (kha) also requires special attention while treating metastatic cancer. Therefore, to achieve ‘khavaigunya –less’ perfect asthi dhatu, rasayana treatment (labhopayo hi shastanam rasdinam rasayanam) of ‘ashti’ becomes inevitable.
Asthi dhatu and vata dosha have ‘ashraya- ashrayee’ (interdependent) relationship. ‘Basti’ is an ideal treatment for ‘vata dosha’ related diseases. Therefore, ‘basti’ is an ideal procedure to treat ‘kha vaigunya’ in asthi dhatu. ‘Rajayapana basti’ is a type of ‘basti’ in which a specific formulation, as described in treaties of ayurved, is administered per rectum. It is useful in controlling the cell division.
In the hierarchy of production of dhatu, Asthi dhatu is produced from the Meda dhatu by removing ‘sneha’ from it through process of ‘khara paka’ (Medasa: sneham Aadaya sira snayutvam aapnuyat snayunam ch mridu paka siranam ch tat: khara…) Therfore, rasayana treatment directed at mada dhatu should also benefit as ‘rasayana’ for asthi dhatu.
The herbomineral formulation used internally, is a combination of generic formulations described in ayurvedic treaties. Each of these formulations has a specific role in the management of neoplasm and prevention of its relapse.
According to ayurved, regeneration of cells is carried out by the ‘shukra dhatu’ and is controlled by the ‘vata dosha’. The uncontrolled cell division is a result of imbalance of ‘vata dosha’, which results into neoplasm (The hypothesis of cancer).
As ‘shukra dhatu’ is ‘sarvadehik’, every cell in the body has an inbuilt potential of replication / reproduction, in favorable situations. The ‘akasha’ provides space for accommodation of such multiplying cells (as ‘garbhashaya’ – uterus provides space for growth of embryo). Any space or ‘akasha’ (Kha) is therefore a potential garbhashaya (e.g. test-tube baby). However, if such situation is created in space other than the one designated for the purpose, it is abnormal- ‘Kha-vaigunya’.
Some of the cancerous cells may be carried to such distant places with the circulation, and if they find a suitable place for harboring, they may replicate in that place if the condition is favorable (…Yatra Sanga: Khavaigunyat Vyadhi: tatropjayate). Therefore, a cancer cell can migrate to any place in the body and start multiplying and produce metastatic cancer.
Embryologically, the kidneys are created from the essence of ‘Rakta dhatu’ and ‘Meda dhatu’ (“Rakta Meda Prasadajou Vrukou”). In ayurvedic therapeutics, this reference needs to be viewed in terms of probable mode or route of samprapti (etio-pathology) and its reversal (chikitsa - treatment). Medicines which act on rasa dhatu and meda dhatu would therefore probably be helpful in treating any pathology of Kidney.
In the metastatic bone cancer, ‘Asthi’ predisposed by ‘kha vaigunya’ acts as a site which allows the growth of cells from a distant tissue. This space (kha) also requires special attention while treating metastatic cancer. Therefore, to achieve ‘khavaigunya –less’ perfect asthi dhatu, rasayana treatment (labhopayo hi shastanam rasdinam rasayanam) of ‘ashti’ becomes inevitable.
Asthi dhatu and vata dosha have ‘ashraya- ashrayee’ (interdependent) relationship. ‘Basti’ is an ideal treatment for ‘vata dosha’ related diseases. Therefore, ‘basti’ is an ideal procedure to treat ‘kha vaigunya’ in asthi dhatu. ‘Rajayapana basti’ is a type of ‘basti’ in which a specific formulation, as described in treaties of ayurved, is administered per rectum. It is useful in controlling the cell division.
In the hierarchy of production of dhatu, Asthi dhatu is produced from the Meda dhatu by removing ‘sneha’ from it through process of ‘khara paka’ (Medasa: sneham Aadaya sira snayutvam aapnuyat snayunam ch mridu paka siranam ch tat: khara…) Therfore, rasayana treatment directed at mada dhatu should also benefit as ‘rasayana’ for asthi dhatu.
The herbomineral formulation used internally, is a combination of generic formulations described in ayurvedic treaties. Each of these formulations has a specific role in the management of neoplasm and prevention of its relapse.
Kupitanam hi doshanam sharire paridhavatam ..
Not to allow vitiation
Not to allow spread
Not to allow dosha-dusha samurchana
inherent
Bala Kapha moolam balam
General
Specific
Sahaja – Innate
Kalaj –
Yuktikruta – Acquired
According to ayurved, regeneration of cells is carried out by the ‘shukra dhatu’ and is controlled by the ‘vata dosha’. The uncontrolled cell division is a result of imbalance of ‘vata dosha’, which results into neoplasm (The hypothesis of cancer).
As ‘shukra dhatu’ is ‘sarvadehik’, every cell in the body has an inbuilt potential of replication / reproduction, in favorable situations. The ‘akasha’ provides space for accommodation of such multiplying cells (as ‘garbhashaya’ – uterus provides space for growth of embryo). Any space or ‘akasha’ (Kha) is therefore a potential garbhashaya (e.g. test-tube baby). However, if such situation is created in space other than the one designated for the purpose, it is abnormal- ‘Kha-vaigunya’.
Some of the cancerous cells may be carried to such distant places with the circulation, and if they find a suitable place for harboring, they may replicate in that place if the condition is favorable (…Yatra Sanga: Khavaigunyat Vyadhi: tatropjayate). Therefore, a cancer cell can migrate to any place in the body and start multiplying and produce metastatic cancer.
Embryologically, the kidneys are created from the essence of ‘Rakta dhatu’ and ‘Meda dhatu’ (“Rakta Meda Prasadajou Vrukou”). In ayurvedic therapeutics, this reference needs to be viewed in terms of probable mode or route of samprapti (etio-pathology) and its reversal (chikitsa - treatment). Medicines which act on rasa dhatu and meda dhatu would therefore probably be helpful in treating any pathology of Kidney.
In the metastatic bone cancer, ‘Asthi’ predisposed by ‘kha vaigunya’ acts as a site which allows the growth of cells from a distant tissue. This space (kha) also requires special attention while treating metastatic cancer. Therefore, to achieve ‘khavaigunya –less’ perfect asthi dhatu, rasayana treatment (labhopayo hi shastanam rasdinam rasayanam) of ‘ashti’ becomes inevitable.
Asthi dhatu and vata dosha have ‘ashraya- ashrayee’ (interdependent) relationship. ‘Basti’ is an ideal treatment for ‘vata dosha’ related diseases. Therefore, ‘basti’ is an ideal procedure to treat ‘kha vaigunya’ in asthi dhatu. ‘Rajayapana basti’ is a type of ‘basti’ in which a specific formulation, as described in treaties of ayurved, is administered per rectum. It is useful in controlling the cell division.
In the hierarchy of production of dhatu, Asthi dhatu is produced from the Meda dhatu by removing ‘sneha’ from it through process of ‘khara paka’ (Medasa: sneham Aadaya sira snayutvam aapnuyat snayunam ch mridu paka siranam ch tat: khara…) Therfore, rasayana treatment directed at mada dhatu should also benefit as ‘rasayana’ for asthi dhatu.
The herbomineral formulation used internally, is a combination of generic formulations described in ayurvedic treaties. Each of these formulations has a specific role in the management of neoplasm and prevention of its relapse.
Shodhana of Dosha
No Shodhana of Dhatu
Shodhana of Dosha
No Shodhana of Dhatu
Sitopaladi Churna
Hirak Bhasma
Abhrak bhasma
Suvarna bhasma
Rajata bhasma
Tamra bhasma
Bruhatvata chintamani rasa
Makardhwaja rasa
Sheelajeet
Sitopaladi Churna
Hirak Bhasma
Abhrak bhasma
Suvarna bhasma
Rajata bhasma
Tamra bhasma
Bruhatvata chintamani rasa
Makardhwaja rasa
Sheelajeet
Tamra bham: Tikta, Kahay, Madhur, Ushnaveerya, Vishahara, sarak, laghu, tridhsha hara, anti-obesity,
Yakrut-plihodara, 1/8 to ½ ratti
Sitopaladi Churna
Hirak Bhasma
Abhrak bhasma
Suvarna bhasma
Rajata bhasma
Tamra bhasma
Bruhatvata chintamani rasa
Makardhwaja rasa
Sheelajeet
According to ayurved, regeneration of cells is carried out by the ‘shukra dhatu’ and is controlled by the ‘vata dosha’. The uncontrolled cell division is a result of imbalance of ‘vata dosha’, which results into neoplasm (The hypothesis of cancer).
In the metastatic bone cancer, ‘Asthi’ predisposed by ‘kha vaigunya’ acts as a site which allows the growth of cells from a distant tissue. This space (kha) also requires special attention while treating metastatic cancer. Therefore, to achieve ‘khavaigunya –less’ perfect asthi dhatu, rasayana treatment (labhopayo hi shastanam rasdinam rasayanam) of ‘ashti’ becomes inevitable.
Asthi dhatu and vata dosha have ‘ashraya- ashrayee’ (interdependent) relationship. ‘Basti’ is an ideal treatment for ‘vata dosha’ related diseases. Therefore, ‘basti’ is an ideal procedure to treat ‘kha vaigunya’ in asthi dhatu. ‘Rajayapana basti’ is a type of ‘basti’ in which a specific formulation, as described in treaties of ayurved, is administered per rectum. It is useful in controlling the cell division.
In the hierarchy of production of dhatu, Asthi dhatu is produced from the Meda dhatu by removing ‘sneha’ from it through process of ‘khara paka’ (Medasa: sneham Aadaya sira snayutvam aapnuyat snayunam ch mridu paka siranam ch tat: khara…) Therfore, rasayana treatment directed at mada dhatu should also benefit as ‘rasayana’ for asthi dhatu.
The herbomineral formulation used internally, is a combination of generic formulations described in ayurvedic treaties. Each of these formulations has a specific role in the management of neoplasm and prevention of its relapse.